Fifty-Microliter THC Blood Testing: Sensitivity Does Not Validate Every Collection Method

A validated assay quantified THC using only 50 microliters of whole blood. That analytical achievement does not independently validate roadside finger-prick collection or establish the meaning of a very low result for impairment.

The sensitivity finding

Researchers developed liquid–liquid extraction and LC–MS/MS for six cannabinoids. The lower quantification limit for THC was 0.10 ng/mL. Limits differed for other targets, so one sensitivity figure should not be applied to the entire panel.

The method measured liquid whole blood. Its compatibility with microsampling volumes is distinct from demonstrating that every collection device, capillary specimen and storage procedure produces interchangeable results.

Small preparation changes affected different analytes

Alkalinization improved response for several cannabinoids but slightly reduced THC-COOH response. Protein precipitation also helped some compounds while reducing others. Optimizing parent THC therefore did not automatically optimize its metabolites.

Instrument equilibration mattered too: extending it stabilized response across repeated injections after an initially shorter interval produced signal loss. Repeated injections are tests of analytical consistency, not additional independent human subjects.

Surrogate calibration required examination

The investigators used horse blood for calibration and assessed performance in three sources of drug-free human blood. They examined accuracy, precision, interferences and matrix behavior rather than simply assuming equivalence.

That validation supports the stated laboratory workflow. A different laboratory still needs evidence covering its equipment, specimen handling and collection conditions. Very-low-concentration findings also require careful attention to blanks, contamination and uncertainty.

What a lower quantification limit changes

Greater sensitivity expands the range of exposures a laboratory can measure. It does not make the lowest quantifiable concentration a clinical or legal boundary.

The study supports a practical small-volume assay, not an automatic classification of recent use, impairment or causation. The specimen, analyte and method must be reported accurately before any further interpretation is attempted.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Aman A Mohammed and colleagues. Validation of a microsampling-compatible liquid–liquid extraction method for cannabinoid quantitation in 50 µL of whole blood using liquid chromatography–mass spectrometry. Journal of Analytical Toxicology (2026). DOI: 10.1093/jat/bkag004.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Other Medications Changed THC/CBD Spray Exposure in Different Directions

The effect of another medication on THC/CBD exposure depends on the drug and the pathway involved. A human interaction study found lower cannabinoid exposure with rifampicin, higher exposure with ketoconazole, and no significant pharmacokinetic change with omeprazole under the tested conditions. Three separate crossover comparisons Stott and colleagues studied 36…

Spread the love

Read Article: Other Medications Changed THC/CBD Spray Exposure in Different Directions

An Intermediate CBD Stress Response Was Not a Significant Placebo Difference

A CBD group’s average response can fall between placebo patients and healthy controls without demonstrating a significant CBD-versus-placebo benefit. A study of social stress in people at clinical high risk of psychosis illustrates this statistical distinction. Stress hormones and subjective symptoms were separate endpoints Participants at clinical high risk received…

Spread the love

Read Article: An Intermediate CBD Stress Response Was Not a Significant Placebo Difference

Two-Dimensional Cannabis GC–MS Testing Needs Correctly Timed Transfer Windows

Adding a second chromatography column can improve cannabinoid separation while introducing a new failure point: the analyte must reach the second column during the correct transfer window. A plasma assay study showed why those windows require verification. More separation brought more timing requirements Karschner and colleagues developed two-dimensional gas chromatography–mass…

Spread the love

Read Article: Two-Dimensional Cannabis GC–MS Testing Needs Correctly Timed Transfer Windows

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us